Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basal plus Apidra added to Lantus versus twice-daily premixed insulin in type 2 diabetes
NL-OMON36312Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of human insulin, insulin glargine and biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline to endpoint. Started Feb 2010; status: active, not recruiting.
02
Drugs
human insulininsulin glarginebiphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON36312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36312.